Intrafraction Kolovoltage X-ray Imaging, Lung Cancer, Markerless Image Guidance
Conditions
Keywords
Lung Cancer, Radiotherapy, Fiducials, Markerless Tumour Tracking
Brief summary
In radiotherapy, tumour tracking allows us to ensure the radiation beam is accurately targeting the tumour while it moves in a complex and unpredictable way. Most tumour tracking techniques require the implantation of fiducial markers around the tumour. Markerless Tumour Tracking negates the need for implanted markers, enabling accurate and optimal cancer radiotherapy in a non-invasive way.
Detailed description
We will perform a phase I observational trial investigating the feasibility of the Markerless Tumour Tracking technology. Markerless Tumour Tracking will be integrated with existing treatment machines to provide real-time monitoring of tumour motion during treatment delivery. Eligible patients are implanted with fiducial markers, which act as the ground truth for evaluating the accuracy of Markerless Tumour Tracking. The patients will undergo the current standard of care radiotherapy, with the exception that kilovoltage x-ray images will be acquired continuously during treatment delivery and used to calculate online Markerless Tumour Tracking. Markerless Tumour Tracking determines the mean tumour position calculated over the most recent 15 seconds and displays shifts exceeding 3 mm. The trial will be a single-institution study recruiting only at RNSH Radiation Oncology Department. As this trial investigates feasibility, our focus will be on estimating the proportion of treatment time in which the Markerless Tumour Tracking is within acceptable limits.
Interventions
RADIATIONMarkerless Tumour Tracking
Intrafraction Kolovoltage X-ray Imaging using Fiducials
Sponsors
Royal North Shore Hospital
University of Sydney
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Inclusion criteria
1. Aged 18 or older. 2. Has provided written Informed Consent for participation in this trial and is willing to comply with the study. 3. Patients undergoing external beam radiotherapy. 4. Histologically proven Stage I NSCLC or oligometastatic lung metastases (3 or less). 5. Diagnostic CT prior to insertion of fiducial markers. 6. Patient must be able to have fiducial markers placed in the lung (if on anticoagulants, must be cleared by LMO or cardiologist). 7. ECOG performance status 0-2. 8. A maximum of three metastases to the lung from any non-haematological malignancy. Multiple metastases will be treated separately. 9. 1 cm ≤ Tumour diameter in any dimension ≤ = 5 cm. 10. The distance between the tumour centroid and the top end of the diaphragm is \<=8 cm.
Exclusion criteria
1. Patient has low respiratory performance as evaluated by the physicians. 2. Previous high-dose thoracic radiotherapy. 3. Less than one fiducial marker implanted in the lung. 4. Fiducial markers are too far from the tumour centroid (\>9 cm). 5. Cytotoxic chemotherapy within 3 weeks of commencement of treatment, or concurrently with treatment. Hormonal manipulation agents are allowable (e.g. aromatase inhibitors, selective oestrogen receptor modulators, and gonadotropin releasing hormone receptor modulators). 6. Targeted agents (such as sunitinib, bevacizumab and tarceva) within 7 days of commencement of treatment, concurrently with treatment or 7 days after radiotherapy. 7. Women who are pregnant or lactating. 8. Unwilling or unable to give informed consent. 9. Unwilling or unable to complete quality of life questionnaires.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Markerless Tumour Tracking | 6 months after recruitment | to demonstrate the feasibility of Markerless Tumour Tracking for motion-adaptive lung cancer radiotherapy as assessed by agreement between markerless and marker-based tracking within 3 mm for at least 80% of the beam-on time as assessed in off-line analyses. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Markerless Tumour Tracking outcome | 6 months after treatment of last fraction | To identify cohort of patients on which markerless Tumour tracking performs well or poorly |
| Accuracy | 6 months after treatment of last fraction | To quantify the accuracy of marker-based tracking by comparison with MV-kV triangulation or visual inspection |
| Magnitude | 6 months after treatment of last fraction | To investigate the magnitude of surrogacy of lung tumour motion, ie the difference between tumour motion and implanted marker motion |
| Correlation | 6 months after treatment of last fraction | To investigate the correlation between external and internal motion using infrared/optical imaging |
| Suitability | 6 months after treatment of last fraction | To investigate the suitability and frequency of correcting for tumour baseline shifts based on a variety of tolerance criteria and with different methods |
| Frequency | 6 months after treatment of last fraction | To investigate the frequency of correcting for tumour baseline shifts based on a variety of tolerance criteria and with different methods |
| Feasibility of outcomes prediction | 6 months after treatment of last fraction | To investigate the feasibility of predicting treatment outcomes based on patient and imaging information |
| Outcomes | 6 months after treatment of last fraction | Participants will be followed for 2 years to determine patient outcomes, including radiation therapy toxicity, local control (whether the tumour has spread) and survival |
| Historical | 6 months after treatment of last fraction | 2 year outcomes will be compared to historical outcomes reported from our lung Departmental SBRT database |
| Ineligibility | 6 months after treatment of last fraction | To record the number of patients ineligible after marker insertion due to positioning of markers, or due to complications with the implantation procedure |
| Radiomic Features | 6 months after treatment of last fraction | To investigate the feasibility of extracting radiomic features from CT, CBCT, and kV images to predict tumour volumes, tracking accuracy, treatment response, and patient outcomes. |
| X-ray dose | 6 months after treatment of last fraction | To report additional x-ray dose caused by imaging during treatment |
Countries
Australia
Contacts
PRINCIPAL_INVESTIGATORDasantha Jayamanne, MD
Royal North Shore Hospital
Outcome results
None listed